A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-12-11
Adverse events
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2023-06-09 (study day 173); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-06-24 (study day 188); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-04 (study day 198); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-26 (study day 251); relationship: Y
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-11-23 (study day 340); relationship: not assessed
Data queries
No data queries.